InsiderTrades.com logo
“Fed Proof” Your Bank Account with THESE 4 Simple Steps
From Weiss Ratings   |   Ad
Starting as soon as a few months from now, the United States government will make a sweeping change to bank accounts nationwide. It will give them unprecedented powers to control your bank account.
Learn these 4 simple steps and protect your savings before it’s too late.
Jonathan P. Graham net worth and biography
  • LinkedIn
  • Phone
  • Email
  • Website

Jonathan Graham Biography and Net Worth

EVP of Amgen
Jonathan Graham is executive vice president, general counsel and secretary, responsible for leading Amgen’s global Law function.

Before joining Amgen in 2015, Graham was senior vice president and general counsel at Danaher Corporation. He was responsible for all legal, governance, regulatory, risk, compliance, and EH&S matters. Prior to Danaher, Graham was vice president, Litigation and Legal Policy at General Electric Company and a partner at Williams & Connolly LLP in Washington, D.C.

Graham received a bachelor’s degree in Economics from Pitzer College and a J.D. from the University of Texas. He also served as a law clerk to the Honorable Joseph T. Sneed, U.S. Court of Appeals for the Ninth Circuit.

What is Jonathan P. Graham's net worth?

The estimated net worth of Jonathan P. Graham is at least $8.01 million as of November 8th, 2023. Mr. Graham owns 28,078 shares of Amgen stock worth more than $8,008,126 as of November 21st. This net worth evaluation does not reflect any other assets that Mr. Graham may own. Additionally, Mr. Graham receives an annual salary of $2,440,000.00 as EVP at Amgen. Learn More about Jonathan P. Graham's net worth.

How old is Jonathan P. Graham?

Mr. Graham is currently 63 years old. There are 7 older executives and no younger executives at Amgen. The oldest executive at Amgen is Mr. Peter H. Griffith, Executive VP & CFO, who is 65 years old. Learn More on Jonathan P. Graham's age.

What is Jonathan P. Graham's salary?

As the EVP of Amgen Inc., Mr. Graham earns $2,440,000.00 per year. There are 5 executives that earn more than Mr. Graham. The highest earning executive at Amgen is Mr. Robert A. Bradway, Chairman & Chief Executive Officer, who commands a salary of $6,730,000.00 per year. Learn More on Jonathan P. Graham's salary.

How do I contact Jonathan P. Graham?

The corporate mailing address for Mr. Graham and other Amgen executives is ONE AMGEN CENTER DRIVE, THOUSAND OAKS CA, 91320. Amgen can also be reached via phone at (805) 447-1000 and via email at [email protected]. Learn More on Jonathan P. Graham's contact information.

Has Jonathan P. Graham been buying or selling shares of Amgen?

Jonathan P. Graham has not been actively trading shares of Amgen in the last ninety days. Learn More on Jonathan P. Graham's trading history.

Who are Amgen's active insiders?

Amgen's insider roster includes Robert Bradway (Chairman & Chief Executive Officer), Robert Eckert (Director), Murdo Gordon (EVP), Jonathan Graham (EVP), Peter Griffith (Exec. VP & CFO ), Nancy Grygiel (SVP), Nancy Grygiel (SVP), Ronald Sugar (Director), Ronald Sugar (Director), and R Williams (Director). Learn More on Amgen's active insiders.

Are insiders buying or selling shares of Amgen?

During the last year, insiders at the medical research company sold shares 2 times. They sold a total of 4,213 shares worth more than $1,235,082.41. The most recent insider tranaction occured on May, 3rd when SVP Nancy A Grygiel sold 2,117 shares worth more than $662,811.53. Insiders at Amgen own 0.7% of the company. Learn More about insider trades at Amgen.

Information on this page was last updated on 5/3/2024.

Jonathan P. Graham Insider Trading History at Amgen

See Full Table

Jonathan P. Graham Buying and Selling Activity at Amgen

This chart shows Jonathan P. Graham's buying and selling at Amgen by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Amgen Company Overview

Amgen logo
Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout. It also markets other products, including Neulasta, MVASI, AMJEVITA/AMGEVITA, TEZSPIRE, Parsabiv, Aimovig, LUMAKRAS/LUMYKRAS, EPOGEN, KANJINTI, TAVNEOS, RAVICTI, UPLIZNA and PROCYSBI. The company serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors, as well as direct-to-consumer channels. The company has collaboration agreements with AstraZeneca plc for the development and commercialization of TEZSPIRE; Novartis Pharma AG to develop and commercialize Aimovig; UCB for the development and commercialization of EVENITY; Kyowa Kirin Co., Ltd. for rocatinlimab development and commercialization; and BeiGene, Ltd. for oncology products expansion and development. Amgen Inc. was incorporated in 1980 and is headquartered in Thousand Oaks, California.
Read More

Today's Range

Now: $285.21
Low: $284.14
High: $288.83

50 Day Range

MA: $318.08
Low: $278.76
High: $337.38

2 Week Range

Now: $285.21
Low: $260.68
High: $346.85

Volume

464,487 shs

Average Volume

2,461,076 shs

Market Capitalization

$153.31 billion

P/E Ratio

36.52

Dividend Yield

3.21%

Beta

0.6
“Fed Proof” Your Bank Account with THESE 4 Simple Steps
From Weiss Ratings   |   Ad
Starting as soon as a few months from now, the United States government will make a sweeping change to bank accounts nationwide. It will give them unprecedented powers to control your bank account.
Learn these 4 simple steps and protect your savings before it’s too late.